Izumi City General Hospital

Izumishi, Osaka 594-0073

0 studies enrolling now · 2 studies all time

What they study most

Advanced Malignancies, Gastric, or Gastroesophageal Junction Adenocarcinoma

Studies at this site

• Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies — Completed
• Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma — Completed